Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global enzymatic DNA synthesis market size was valued at USD 109.00 million in 2025. The market is projected to grow from USD 135.06 million in 2026 to USD 598.89 million by 2034, exhibiting a CAGR of 20.46% during the forecast period.
The global market is anticipated to witness substantial growth in the upcoming years. The increasing demand for rapid and accurate synthetic DNA across synthetic biology, genomics, gene editing, cell and gene therapy, and other novel biopharmaceutical research is driving this growth. Key biotechnology companies are focusing on developing enzyme-based synthesis platforms that can overcome the length, complexity, and scalability limitations associated with conventional chemical DNA synthesis. Continued advancements in enzymatic synthesis technologies are expected to improve turnaround times and enable researchers to produce increasingly complex DNA sequences. Moreover, expanding applications of synthetic DNA in advanced therapeutics, diagnostics, protein engineering, and genomic engineering are expected to propel the growth of the market during the forecast period.
Major players in the market comprise Touchlight Genetics Limited, DNA Script, SAS, Elegen Corporation, and Ansa Biotechnologies, Inc. These companies are actively participating in strategic collaborations and acquisitions to expand their offerings, diversify their product portfolios, enhance market access, and strengthen their market presence.
Growing Adoption of Decentralized, Automated, and On-Demand DNA Synthesis to Emerge as a Prominent Trend
The shift toward decentralized and on-demand DNA synthesis is one of the significant market trends. Conventional DNA procurement often depends on centralized synthesis facilities and external suppliers, which can increase turnaround times and create logistical constraints for research laboratories. Enzymatic synthesis is enabling automated benchtop platforms that allow researchers to manufacture oligonucleotides directly within their laboratories. The growing adoption of these platforms can provide researchers with greater workflow control, faster design-build-test cycles, and reduced dependence on external DNA supply chains. Such continued improvements in automation, synthesis throughput, and workflow integration are expected to accelerate the adoption of decentralized DNA production.
Download Free sample to learn more about this report.
Rising Demand for Long, Complex, and High-Fidelity DNA for Genetic Medicines and Genome Engineering to Drive Market Growth
The increasing demand for long, complex, and high-fidelity synthetic DNA across genetic medicines and genome engineering applications is expected to drive the global enzymatic DNA synthesis market growth. The development of gene therapies, engineered cell therapies, gene synthesis, vaccines, genome-edited organisms, and advanced biological products increasingly requires DNA constructs containing large coding sequences, regulatory elements, repetitive regions, and other difficult-to-synthesize motifs. Enzymatic DNA synthesis technologies are being developed to enable more accurate production of challenging DNA constructs while reducing extensive assembly and error-correction requirements. Furthermore, increasing research and commercial activity in gene therapy and genome engineering is expected to strengthen the demand for reliable synthesis of longer and more complex DNA, supporting market growth during the forecast period.
Market Drivers - Impact & CAGR Contribution (2026–2034)
| Rank | Market Drivers | Expected Impact on Market Growth | Estimated Gross Market Growth Contribution (USD Million) | Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Rising demand for long, complex, and high-fidelity DNA for genetic medicines and genome engineering | High | 133.65 | High | High | High |
| 2 | Cell-free/enzymatic substitution versus chemical DNA synthesis and conventional plasmid workflows | High | 119.33 | Medium | High | High |
| 3 | Expansion of synthetic biology, engineered biology, and high-frequency design-build-test-learn workflows | High | 100.24 | High | High | Medium |
| 4 | Growth in on-site/benchtop DNA synthesis and workflow automation | Medium-High | 85.92 | Medium | High | High |
| 5 | Increasing GMP/clinical adoption of enzymatic DNA templates and therapeutic starting materials | Medium | 71.60 | Medium | Medium | High |
| 6 | Others (regional commercialization, lower cost per base, broader diagnostics/genomics adoption, and data-storage R&D and licensing) | Low | 38.19 | Low | Low | Low |
| Total Positive Growth Contribution | 548.93 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
High Cost and Scale Requirements and Established DNA Production Alternatives to Restrain Market Growth
The cost and scale economics associated with enzymatic DNA synthesis are expected to restrain the growth of the global market. Conventional phosphoramidite-based DNA synthesis remains highly competitive for routine and shorter DNA sequences. At the same time, plasmid-based production and cloning workflows continue to be widely used across research and genetic medicine development. The availability, familiarity, and established economics of these incumbent methods can limit the willingness of laboratories and biopharmaceutical companies to switch to newer enzymatic platforms. Consequently, the requirement to achieve competitive manufacturing economics while displacing established workflows may restrict the broader service adoption during the forecast period.
Market Restraints - Impact & Negative CAGR Contribution (2026–2034)
| Rank | Market Restraints | Expected Impact on Market Growth | Estimated Reduction in Market Size (USD Million) | Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Cost and scale economics plus strong incumbent chemical/plasmid alternatives | High | 36.00 | High | High | Medium |
| 2 | Fidelity, yield, length and process-standardization constraints across emerging platforms | Medium-High | 24.00 | High | Medium | Medium |
| 3 | Regulatory, biosafety, sequence-screening and validation burden | Medium | 16.00 | Medium | Medium | Low |
| 4 | Others (customer qualification cycles, funding volatility, IP concentration and fragmented standards) | Low | 9.10 | Low | Low | Low |
| Total Negative Growth Impact | 85.1 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
Expansion of GMP-Compatible and Therapeutic-Grade DNA Starting Materials to Create Lucrative Growth Opportunities
The expansion of enzymatic DNA synthesis from primarily research-grade applications toward GMP-compatible and therapeutic-grade DNA starting materials is expected to create significant growth opportunities for market players. The increasing development of mRNA therapeutics, personalized vaccines, gene therapies, engineered cell therapies, and other nucleic acid-based medicines is generating the demand for DNA templates with high purity, sequence accuracy, consistency, and traceability. As enzymatic synthesis platforms advance in scalability, quality systems, analytical validation, and GMP compatibility, manufacturers could extend their offerings from discovery and preclinical research into clinical development and commercial biomanufacturing workflows. This transition would substantially increase the addressable market and enable enzymatic DNA synthesis providers to capture higher-value applications across the genetic medicines industry.
Limited Commercial Scale Validation of Enzymatic DNA Synthesis Technologies May Hinder Wider Adoption
The limited commercial scale validation of DNA synthesis technologies remains an important challenge for the global market. Although enzymatic platforms have demonstrated advantages in speed, sequence complexity, decentralization, and reduced use of hazardous chemicals, several technologies are still progressing from laboratory and research-scale applications toward high-throughput and large-scale DNA manufacturing. Scaling these platforms requires consistent synthesis yield, sequence fidelity, reproducibility, purification efficiency, and cost performance across substantially larger production volumes. Moreover, pharmaceutical and biotechnology companies require robust validation before integrating new DNA synthesis technologies into critical therapeutic development and manufacturing workflows. The requirement for additional scale-up studies, process optimization, and real-world commercial validation may, therefore, lengthen adoption cycles and restrict the near-term penetration of enzymatic approaches compared to established DNA manufacturing technologies.
DNA Synthesis Services Segment Led the Market due to Growing Preference for Outsourced Access to Advanced DNA Synthesis Capabilities
Based on product type, the market is categorized into instruments & platforms, reagents & consumables, DNA synthesis services, and software & other solutions.
The DNA synthesis services segment dominated the market in 2025. Pharmaceutical, biotechnology, and academic organizations increasingly require customized DNA without making substantial investments in specialized synthesis instruments and quality control infrastructure. The enzymatic synthesis of long and complex constructs requires considerable technical expertise and outsourcing allows researchers to obtain sequence-verified and application-ready DNA while reducing internal workflow complexity. Consequently, the combination of lower upfront requirements, access to specialized capabilities, and increasing demand for customized DNA supported the higher adoption of DNA synthesis services.
The software & other solutions segment is expected to grow at a CAGR of 21.93% over the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Higher Commercial Maturity and Efficient Template-Free DNA Extension Supported TdT-Based Enzymatic Synthesis Segment Dominance
Based on technology, the market is segmented into TdT-based enzymatic synthesis, polymerase-based enzymatic synthesis, ligation-based enzymatic synthesis, and other enzymatic synthesis technologies.
In 2025, the TdT-based enzymatic synthesis segment captured the largest market share. The segment dominance is due to the suitability of terminal deoxynucleotidyl transferase for template-free DNA synthesis, which enables controlled synthesis of user-defined DNA sequences without requiring an existing DNA template. Moreover, TdT-based approaches have progressed further toward commercial benchtop platforms, integrated reagent systems, and automated workflows compared to several alternative enzymatic synthesis approaches. The presence of commercially available platforms using this mechanism has, therefore, increased technology awareness and practical utilization, supporting the segment's dominant position.
The polymerase-based enzymatic synthesis segment is projected to grow at a CAGR of 22.39% during the forecast period.
Linear Single-Stranded DNA Segment Led the Market due to Broad Utilization across CRISPR-related Workflows and Assay Development
Based on DNA output type, the market is segmented into linear single-stranded DNA, linear double-stranded DNA, circular single-stranded DNA, circular double-stranded DNA, and others.
In 2025, the linear single-stranded DNA segment accounted for the largest enzymatic DNA synthesis market share. The dominance of the segment is due to its extensive utilization as a fundamental input across PCR, sequencing, gene assembly, mutagenesis, CRISPR-related workflows, assay development, and synthetic biology research. The comparatively straightforward production workflow and the large recurring requirement for customized oligonucleotides across research laboratories increases both synthesis volume and frequency of use. Consequently, broad application diversity and direct compatibility with enzymatic synthesis platforms supported the dominance of the segment.
The circular double-stranded DNA segment is projected to grow at a CAGR of 22.67% during the forecast period.
Increasing Requirement for Customized DNA Constructs in Genome Modification Supported the Dominance of Gene & Genome Engineering
Based on application, the market is segmented into gene & genome engineering, therapeutic & vaccine development, protein & antibody engineering, molecular diagnostics, genomics & sequencing, synthetic biology, DNA data storage, and others.
The gene & genome engineering accounted for the largest market share in 2025. Genome-editing and synthetic-biology workflows require a continuous supply of customized DNA for CRISPR experiments, gene assembly, genomic integration, pathway engineering, transgenic model generation, and large-scale genome redesign. Enzymatic DNA synthesis expands the accessible sequence design space and can shorten the time between DNA design and experimental testing. As a result, the increasing adoption of genome editing and iterative design-build-test workflows directly increases the demand for rapid and high-fidelity synthetic DNA, supporting the segment's dominant position.
The DNA data storage segment is projected to grow at a CAGR of 26.03% during the forecast period.
Pharmaceutical & Biotechnology Companies Segment Led the Market due to Expanding Consumption across Cell & Gene Therapy Development
Based on end user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & genomics companies, CROs & CDMOs, academic & research institutions, and others.
The pharmaceutical & biotechnology companies segment dominated the market in 2025 owing to the substantial consumption of custom DNA across drug discovery, cell & gene therapy development, vaccine research, antibody engineering, protein optimization, synthetic biology, and nucleic acid therapeutics. These companies conduct large numbers of iterative experiments and require DNA with high sequence accuracy, reproducibility, and increasingly greater length and complexity. Furthermore, the growing pipeline of genetic medicines is increasing the requirement for synthetic DNA from early discovery through preclinical development and therapeutic manufacturing workflows. Higher R&D expenditure and the ability of biopharmaceutical companies to adopt premium, advanced synthesis technologies consequently generate greater commercial demand compared to other segments.
The CROs & CDMOs segment is projected to grow at a CAGR of 22.65% over the forecast period.
By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.
North America Enzymatic DNA Synthesis Market Size, 2025 (USD Million)
To get more information on the regional analysis of this market, Download Free sample
North America was valued at USD 36.32 million in 2024 and accounted for a leading position with a value of USD 48.60 million in 2025. The market is growing in North America due to the strong presence of synthetic biology, genomics, gene therapy, and biotechnology companies that require rapid access to customized DNA. High R&D spending and early adoption of automated and benchtop DNA synthesis platforms further support regional demand.
Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated to reach around USD 55.36 million in 2026, accounting for roughly 40.99% of the global market.
The Europe market is projected to grow at a CAGR of 19.17% over the forecast period. The region is anticipated to reach a valuation of USD 36.52 million by 2026, becoming the second-largest market by region. The Europe market growth is supported by expanding research in synthetic biology, advanced therapeutics, and genome engineering across major biotechnology hubs in the U.K., Germany, France, and other European countries. Increasing investments in localized biomanufacturing and nucleic acid-based therapeutics are also creating demand for advanced DNA synthesis technologies.
The U.K. market is estimated to reach USD 8.09 million in 2026, accounting for roughly 5.99% of the global market.
The Germany market is projected to reach approximately USD 8.74 million in 2026, equivalent to around 6.47% of the global market.
The Asia Pacific market is estimated to reach USD 31.54 million in 2026 and secure the third-largest position in the market. The market is expanding rapidly due to growing investments in domestic life-science infrastructure and demand for faster, locally available DNA synthesis services
The Japan market is estimated to touch around USD 7.57 million in 2026, accounting for approximately 5.61% of the global market.
The China market is projected to be among the largest markets worldwide, with 2026 revenues estimated to reach USD 9.45 million, accounting for approximately 7.00% of global sales.
The India market is estimated to touch around USD 3.22 million in 2026, accounting for roughly 2.39% of global revenue.
Latin America is expected to witness moderate growth during the forecast period. The market in Latin America is estimated to reach a valuation of USD 4.46 million in 2026. The regional market growth is being supported by the gradual expansion of molecular biology, genomics, and biotechnology research across Brazil, Mexico, Argentina, and other regional markets. In the Middle East & Africa, the GCC is set to reach USD 1.37 million in 2026.
The South Africa market is projected to reach approximately USD 0.09 million by 2026, accounting for roughly 0.66% of global revenue.
Leading Companies Emphasize Sequence Fidelity and DNA Length to Consolidate their Industry Foothold
The global enzymatic DNA synthesis market is characterized by innovation-driven competition among specialized synthetic DNA companies and established life-science technology providers. DNA Script SAS, Ansa Biotechnologies, Inc., Touchlight Genetics Limited, Elegen Corporation, and 4basebio PLC maintain prominent positions through differentiated enzymatic and cell-free DNA synthesis technologies. These companies are focusing on improving DNA length, sequence fidelity, synthesis speed, difficult-sequence capability, automation, scalability, and therapeutic-grade manufacturing. Therefore, technological performance, ability to synthesize increasingly complex DNA constructs, turnaround time, and expansion into genetic medicine applications are becoming major areas of competitive differentiation.
Other companies are strengthening their positions through specialized synthesis platforms, long and complex DNA capabilities, decentralized production, enzyme engineering, and therapeutic-grade DNA manufacturing. Companies such as Telesis Bio Inc., Camena Bioscience Limited, Ribbon Bio GmbH, and Moligo Technologies AB participate across different areas of the enzymatic DNA synthesis ecosystem. Consequently, factors such as synthesis accuracy, construct length and complexity, scalability, pricing, automation, GMP compatibility, strategic collaborations, and geographical expansion are expected to contribute to these companies’ market presence.
The global enzymatic DNA synthesis market report provides market size estimates and forecasts for all key segments covered in the study. The market outlook also evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. Additionally, the report presents a comprehensive market analysis and a detailed competitive landscape covering estimated market shares, strategic collaborations, geographical presence, recent developments, and profiles of key market participants.
Request for Customization to gain extensive market insights.
| ATTRIBUTE | DETAILS |
| Study Period | 2021-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2021-2024 |
| Growth Rate | CAGR of 20.46% from 2026 to 2034 |
| Unit | Value (USD Million) |
| Segmentation | By Product Type, Technology, DNA Output Type, Application, End User, and Region |
| By Product Type |
|
| By Technology |
|
| By DNA Output Type |
|
| By Application |
|
| By End User |
|
| By Region |
|
According to Fortune Business Insights, the global market value stood at USD 109.00 million in 2025 and is projected to reach USD 598.89 million by 2034.
In 2025, North America’s market value stood at USD 48.60 million.
The market is expected to grow at a CAGR of 20.46% over the forecast period of 2026-2034.
The DNA synthesis services segment led the market based on product type in 2025.
The rising demand for long, complex, and high-fidelity DNA for genetic medicines and genome engineering is a key factor driving market growth.
Touchlight Genetics Limited, DNA Script, SAS, Elegen Corporation, and Ansa Biotechnologies, Inc. are among the major players in the global market.
North America dominated the market in 2025.
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Related Reports
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.